Baxter International heads into its July 30 earnings release with short sellers pulling back sharply and options traders turning more bullish — an unusual combination for a stock the Street is still divided on.
The most striking development this week is a dramatic unwind in short positioning. Short interest dropped roughly 8.5% over the past five trading days, falling from around 41.6 million shares to 38.3 million — now at 7.4% of the free float. That's a meaningful retreat, and it happened in a single sharp step: almost the entire reduction came between July 8 and July 10, when nearly 3.3 million shares were covered in one session. Borrow conditions do nothing to explain urgency on either side. Cost to borrow is negligible at 0.55%, essentially flat on the week. Availability is running at 205% of outstanding short interest — well above its 52-week low of 127% — meaning there is no shortage of shares to borrow for anyone who wants to build a new short position. The covering wasn't forced; it was a choice. Options reinforce the picture. The put/call ratio has dropped to 0.46, almost a full standard deviation below its 20-day average of 0.63. The past month showed a clear regime change: through mid-June the PCR was running above 0.83, consistent with heavy downside hedging. That protective overhang has been unwound almost entirely heading into results.
The Street's reaction this week supports the more constructive tone. Goldman Sachs raised its price target on BAX from $19 to $21 yesterday while holding a Neutral rating — a meaningful signal given Goldman's prior February cut took the target down to $17. Evercore ISI also lifted its target, from $22 to $24 with an Outperform rating, earlier in the month. Both moves come against the backdrop of a stock trading at $21.80, right around the consensus mean target of $21.88. That clustering tells its own story: the Street sees limited upside from here but is no longer positioned for meaningful downside. The bull/bear divide is genuine, though. Citigroup downgraded to Sell in late May with a $17 target. Barclays remains Overweight at $27, and Morgan Stanley holds an Underweight. On valuation, the stock trades at a PE of roughly 11x and an EV/EBITDA of 9.4x — modest multiples for a healthcare equipment name, consistent with the value tilt flagged in recent ORTEX stock score analysis. EPS surprise ranks in only the 11th percentile, a persistent soft spot. Forward EPS momentum on a 12-month basis ranks in the 67th percentile, suggesting estimates are at least trending the right direction heading into the print.
Institutional ownership adds a layer of stability to the story. BlackRock holds 15.4% of shares, with Pzena Investment Management at 12.5% and Dodge & Cox at 11.1% — a concentrated ownership base that leans toward patient, value-oriented mandates. Fidelity (FMR LLC) added around 6.7 million shares through June 30, the largest single reported change among the top holders, suggesting at least one active manager saw enough value to add meaningfully into the weakness. Insider activity is less interesting: all recent trades were small-lot sales by divisional and senior vice president-level executives in early March, with aggregate 90-day net activity minimal relative to shares outstanding. Nothing in the insider record changes the thesis.
Earnings history gives some reason for calm. The last two quarterly prints both delivered modest positive 1-day moves — just under 2% each time — with the five-day drift running above 3-7%. That's a pattern of muted but consistently positive immediate reactions, which may partly explain why options traders are no longer paying heavily for downside protection. The ORTEX short score has edged down from 63.5 on July 6 to 60.2 today, moving in the same direction as the short interest drawdown. Peer context is worth noting: GEHC fell nearly 5% on the week and COO dropped about 4.7%, making BAX's 4.6% weekly decline look more like sector-wide pressure than company-specific deterioration. CNMD was the outlier, surging 22% on the week for unrelated reasons.
The setup going into July 30 is less about whether shorts are crowded — they are covering — and more about whether the modest consensus targets leave enough room for a positive surprise to matter.
See the live data behind this article on ORTEX.
Open BAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
